


Figure S21



**Siltuximab treatment initiated after establishment of disease also improves anemia and overall survival in human AML xenografts.** NSG<sup>spIn-</sup>-PDX mice engrafted with SU540 were treated with control antibody or siltuximab (20 mg/kg) every 3 days starting on day 21. (A) The decline in hemoglobin was delayed in the siltuximab treatment group (\*\*p<0.01, \*\*\*p<0.001, unpaired t-test). (B) BM leukemic burden (hCD45<sup>+</sup>CD33<sup>+</sup>) was similar between treatment groups. N.S.= not significant. (C) Overall survival was improved with siltuximab treatment (11.5 weeks vs 14.5 weeks, \*\*p=0.003, log rank test).